Table II.
Summary of Gene Expression Levels in Patients Pre and Post Flavopiridol Treatment (n=16)
| BCL-2 | HMGA1 | STAT3 | E2F1 | POLR2A | MCL-1 | VEGFA | CCND1 | |
|---|---|---|---|---|---|---|---|---|
| All (16) | ||||||||
| Mean Pre | 3.58 | 2.48 | 3.73 | 0.55 | 1.36 | 18.9 | 1.05 | 0.88 |
| Range Pre | 0.19-9.97 | 0.81-4.88 | 0.24-14.64 | 0.00-1.12 | 0.54-2.90 | 3.36-55.75 | 0.02-0.80 | 0.12-10.84 |
| Mean Post | 19.38 | 1.08 | 2.68 | 0.11 | 0.76 | 19.58 | 0.76 | 4.22 |
| Range Post | 0.54-63.17 | 0.32-2.28 | 0.07-13.43 | 0.00-0.45 | 0.23-1.54 | 1.67-39.42 | 0.00-4.92 | 0.00-29.24 |
| **p Value % of patients with p≤0.05 |
p=0.0005
(100%) |
p=0.0005
(81.2%) |
p=0.041
(68.7%) |
p=0.009
(56.3%) |
p=0.034
(83.3%) |
p=0.518 (93.7%) |
p=0.103 (75%) |
p=0.104 (37.5%) |
|
| ||||||||
| CR(5) | ||||||||
| Mean Pre | 6.00 | 2.36 | 4.31 | 0.68 | 1.06 | 18.49 | 1.61 | 0.13 |
| Range Pre | 1.35-9.48 | 0.75-6.42 | 0.23-11.25 | 0.05-2.46 | 0.39-2.90 | 6.07-27.84 | 0.51-2.86 | 0.01-0.33 |
| Mean Post | 33.13 | 0.84 | 3.26 | 0.14 | 0.59 | 29.87 | 1.11 | 5.76 |
| Range Post | 4.02-63.17 | 0.50-1.30 | 0.07-9.66 | 0.01-0.31 | 0.23-1.54 | 19.69-37.16 | 0.05-4.83 | 0.04-25.90 |
| **p Value % of patients with p≤0.05 |
p=0.0625 (100%) |
p=0.0625 (60%) |
p=0.0625 (80%) |
p=0.0625 (80%) |
p=0.0625 (60%) |
p=0.62 (80%) |
p=0.125 (100%) |
p=0.125 (60%) |
|
| ||||||||
| NR(8) | ||||||||
| Mean Pre | 2.79 | 2.96 | 2.34 | 0.52 | 1.58 | 12.51 | 0.45 | 1.65 |
| Range Pre | 0.19-9.97 | 0.60-5.90 | 0.07-6.31 | 0.00-1.84 | 0.44-2.70 | 2.67-38.74 | 0.02-1.94 | 0.01-10.84 |
| Mean Post | 15.89 | 1.34 | 1.36 | 0.073 | 0.87 | 10.51 | 0.73 | 4.32 |
| Range Post | 0.54-54.70 | 0.43-2.28 | 0.10-3.59 | 0.00-0.38 | 0.43-1.40 | 1.67-19.04 | 0.00-4.92 | 0.00-29.24 |
| **p Value % of patients with p≤0.05 |
p=0.039
(100%) |
p=0.008 (87.5%) |
p=0.023
(62.5%) |
p=0.078 (37.5%) |
p=0.015
(100%) |
p=0.039
(100%) |
p=0.19 (50%) |
p=0.47 (37.5%) |
|
| ||||||||
| PR(2) | ||||||||
| Mean Pre | 2.37 | 0.68 | 8.95 | 0.092 | NA | 35.03 | 1.18 | NA |
| Range Pre | 1.52-3.21 | 0.56-0.81 | 3.25-14.64 | 0.04-0.14 | NA | 14.33-55.75 | 0.41-1.94 | NA |
| Mean Post | 7.62 | 0.33 | 7.29 | 0.041 | NA | 22.95 | 0.11 | NA |
| Range Post | 1.78-13.46 | 0.32-0.35 | 1.15-13.43 | 0.00-0.08 | NA | 6.48-39.42 | 0.09-0.13 | NA |
| **p Value % of patients with p≤0.05 |
p=0.50 (100%) |
p=0.25 (100%) |
p=0.25 (50%) |
p=0.25 (50%) |
NA | p=0.25 (100%) |
p=0.25 (100%) |
NA |
This table summarizes the gene expression changes (increased or decreased expression) for the 12 AML cases. CR-Complete remission; PR-Partial Response; NR-No response; NE-Non-evaluable.
*
(W) p-value; statistical significance assigned by the Wilcoxon signed-rank test.